Sepracor Reports Preliminary Phase III Study Results For OMNARIS(R) HFA Nasal Aerosol In Seasonal Allergic Rhinitis Sepracor Inc. (Nasdaq: SEPR) announced the results of a large-scale, 707-patient Phase III study of OMNARIS® (ciclesonide) HFA, an aerosol nasal formulation of ciclesonide, for the treatment of seasonal allergic rhinitis (SAR) in adult and adolescent patients.
Source: www.medicalnewstoday.comMerz Pharmaceuticals Announces Results Of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) Results from two prospective, double-blind placebo controlled multi-center studies in patients with cervical dystonia and blepharospasm, and pooled European efficacy and safety data in patients with focal dystonia and upper limb spasticity will be presented at the American Academy of Neurology's (AAN) 61st annual meeting in Seattle. The studies were sponsored by Merz Pharmaceuticals, which plans to file a Biologic License Application (BLA) for NT-201 in the USA in the near future.
Source: www.medicalnewstoday.comIn Clinical Trial Anti-Aging Cosmetic Reduced Wrinkles Scientists testing a cosmetic anti-ageing product sold on the high street have shown it can clinically reduce wrinkles and improve the appearance of skin damaged by everyday exposure to sunlight. Dermatologists at The University of Manchester carried out a clinical trial on 60 volunteers with typical signs of sun-damaged skin and found that the cosmetic, No7 Protect & Perfect Intense Beauty Serum, could improve some of these clinical features.
Source: www.medicalnewstoday.comDendreon Presents Preclinical Data Demonstrating Activity Of TRPM8 Agonist, D-3263, In Benign Prostatic Hyperplasia Researchers from Dendreon Corporation (Nasdaq: DNDN) presented preclinical data demonstrating the potential of D-3263, Dendreon's orally bioavailable small molecule, which targets TRPM8 (a transmembrane cation channel protein), to treat benign prostatic hyperplasia (BPH). D-3263 demonstrated the ability to reduce BPH alone and in combination with finasteride, a current treatment for BPH.
Source: www.medicalnewstoday.comMeasuring Adherence With Claims Data For Schizophrenic Patients Medication non-adherence is commonly associated with adverse health conditions and increased economic burden to the health care system and is a critical issue especially in case of chronic therapies such as schizophrenia. Due to its usefulness in recent years, administrative claims data has been one of the most commonly used sources for calculating medication adherence.
Source: www.medicalnewstoday.com
# posted by Network @ 1:19 PM
